. Histologie, . De-boeck, and . Supérieur, , 2020.

, Primary Central Nervous System Tumors: Pathogenesis and Therapy, 2011.

I. R. Whittle, C. Smith, P. Navoo, D. Collie, and . Meningiomas, The Lancet, vol.363, pp.1535-1543, 2004.

A. R. Brodbelt, The outcome of patients with surgically treated meningioma in England: 1999-2013. A cancer registry data analysis, Br. J. Neurosurg, vol.33, pp.641-647, 2019.

F. Ah-pine and A. Rousseau, Tumeurs primitives du système nerveux central -Classifications histologique et topographique, et épidémiologie, pp.17-83172, 2018.

D. N. Louis, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol. (Berl.), vol.131, pp.803-820, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

P. N. Harter, Y. Braun, and K. H. Plate, Classification of meningiomas-advances and controversies. Chin, Clin. Oncol, vol.6, p.3, 2017.

R. A. Vaubel, Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature, J. Neuropathol. Exp. Neurol, vol.75, pp.44-52, 2016.

C. Champeaux, J. Weller, and S. Katsahian, Epidemiology of meningiomas. A nationwide study of surgically treated tumours on French medico-administrative data, Cancer Epidemiol, vol.58, pp.63-70, 2019.

C. L. Anzalone, A. E. Glasgow, J. J. Van-gompel, and M. L. Carlson, Racial Differences in Disease Presentation and Management of Intracranial Meningioma, J. Neurol. Surg. Part B Skull Base, vol.80, pp.555-561, 2019.

I. Baldi, Epidemiology of meningiomas. Neurochirurgie, vol.64, pp.5-14, 2018.

R. A. Buerki, An overview of meningiomas, Future Oncol, vol.14, pp.2161-2177, 2018.

W. Masalha, Survival and Prognostic Predictors of Anaplastic Meningiomas. World Neurosurg, vol.131, pp.321-328, 2019.

S. T. Magill, Relationship between tumor location, size, and WHO grade in meningioma, Neurosurg. Focus, vol.44, p.4, 2018.

R. A. Kessler, Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature. World Neurosurg, vol.101, pp.47-56, 2017.

R. Goldbrunner, EANO guidelines for the diagnosis and treatment of meningiomas, Lancet Oncol, vol.17, pp.383-391, 2016.

T. Lilo, Spectrochemical differentiation of meningioma tumours based on attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy, Anal. Bioanal. Chem, 2019.

M. Nowosielski, Diagnostic challenges in meningioma, Neuro-Oncol, vol.19, pp.1588-1598, 2017.

J. Li, R. Liang, C. Song, Y. Xiang, and Y. Liu,

, Expression in Meningioma Patients: A Meta-Analysis, Crit. Rev. Eukaryot. Gene Expr, vol.29, pp.141-150, 2019.

H. Be?uli?, Correlation of Peritumoral Brain Edema with Morphological Characteristics and Ki67 Proliferative Index in Resected Intracranial Meningiomas, Acta Clin. Croat, 2019.

T. Graillon, Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review, J. Neurosurg, vol.127, pp.660-669, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01478922

B. M. Dijkstra, H. Jeltema, S. Kruijff, and R. J. Groen, The application of fluorescence techniques in meningioma surgery-a review, Neurosurg. Rev, vol.42, pp.799-809, 2019.

Y. Ding, Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas, Ann. Clin. Lab. Sci, vol.38, pp.344-351, 2008.

W. L. Bi and I. F. Dunn, Current and emerging principles in surgery for meningioma, Clin. Oncol, vol.6, pp.7-7, 2017.

N. Wang and M. Osswald, Meningiomas: Overview and New Directions in Therapy, Semin. Neurol, vol.38, pp.112-120, 2018.

J. Lemée, M. V. Corniola, and T. R. Meling, Benefits of re-do surgery for recurrent intracranial meningiomas, Sci. Rep, vol.10, p.303, 2020.

H. Rapport, , vol.1

F. Nigim, H. Wakimoto, E. Kasper, L. Ackermans, and Y. Temel, Emerging Medical Treatments for Meningioma in the Molecular Era, Biomedicines, vol.6, p.86, 2018.

T. Kaley, Historical benchmarks for medical therapy trials in surgery-and radiationrefractory meningioma: a RANO review, Neuro-Oncol, vol.16, pp.829-840, 2014.

A. Franke, Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review, Surg. Neurol. Int, vol.9, p.133, 2018.

T. Graillon, Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro, Oncotarget, vol.8, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01731578

Y. Ji, Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005, J. Clin

, Oncol. Off. J. Am. Soc. Clin. Oncol, vol.33, pp.4093-4098, 2015.

V. A. Venur, S. Santagata, E. Galanis, and P. Brastianos, New molecular targets in meningiomas: the present and the future, Curr. Opin. Neurol, vol.31, pp.740-746, 2018.

D. Juric, Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA -Altered Solid Tumors: Results From the First-in-Human Study, J. Clin. Oncol, vol.36, pp.1291-1299, 2018.

T. Graillon, Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial, Clin. Cancer Res, vol.26, pp.552-557, 2020.
URL : https://hal.archives-ouvertes.fr/hal-02457059

S. Ardern-holmes, G. Fisher, and K. North, Neurofibromatosis Type 2, J. Child Neurol, vol.32, pp.9-22, 2017.

M. J. Smith, Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas, Nat. Genet, vol.45, pp.295-298, 2013.

I. Christiaans, Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas, J. Med. Genet, vol.48, pp.93-97, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00573999

, Hidden association of Cowden syndrome, PTEN mutation and meningioma frequency, Oncoscience, vol.149, 2016.

C. Chau, Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines, Cancers, vol.11, 2019.

G. Askaner, U. Lei, B. Bertelsen, A. Venzo, and K. Wadt, Novel SUFU Frameshift Variant Leading to Meningioma in Three Generations in a Family with Gorlin Syndrome. Case Rep, Genet, vol.2019, pp.1-5, 2019.

W. L. Bi, V. C. Prabhu, and I. F. Dunn, High-grade meningiomas: biology and implications, Neurosurg. Focus, vol.44, p.2, 2018.

Y. S. Lee and Y. S. Lee, Molecular characteristics of meningiomas, J. Pathol. Transl. Med, vol.54, pp.45-63, 2020.

A. M. Petrilli and C. Fernández-valle, Role of Merlin/NF2 inactivation in tumor biology, Oncogene, vol.35, pp.537-548, 2016.

S. Lee, The Role of Merlin/NF2 Loss in Meningioma Biology, Cancers, vol.11, p.1633, 2019.

V. E. Clark, Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO, Science, vol.339, pp.1077-1080, 2013.

T. Zotti, I. Scudiero, P. Vito, and R. Stilo, The Emerging Role of TRAF7 in Tumor Development: TRAF7 IN TUMOR DEVELOPMENT, J. Cell. Physiol, vol.232, pp.1233-1238, 2017.

P. Xie, TRAF molecules in cell signaling and in human diseases, J. Mol. Signal. 8, Art, vol.7, 2013.

H. Tang, KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas, J. Mol. Cell Biol, vol.9, pp.315-324, 2017.

N. Chalhoub and S. J. Baker, PTEN and the PI3-Kinase Pathway in Cancer, Annu. Rev. Pathol, vol.4, pp.127-150, 2009.

Y. Jia, Y. Wang, and J. Xie, The Hedgehog pathway: role in cell differentiation, polarity and proliferation, Arch. Toxicol, vol.89, pp.179-191, 2015.

J. Boetto, F. Bielle, M. Sanson, M. Peyre, and M. Kalamarides, SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas, Neuro-Oncol, vol.19, pp.345-351, 2017.

S. Yuzawa, H. Nishihara, and S. Tanaka, Genetic landscape of meningioma, Brain Tumor Pathol, vol.33, pp.237-247, 2016.

K. Kerr, K. Qualmann, Y. Esquenazi, J. Hagan, and D. H. Kim, Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease

, Neurosurgery, 2018.

S. Couvé, B. Bouadjar, M. Avril, A. Sarasin, and L. Daya-grosjean, Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients, Cancer Res, vol.62, pp.7186-7195, 2003.

A. Biczok, TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas, J. Neurooncol, vol.139, pp.671-678, 2018.

A. Guyot, Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma, J. Neurooncol, vol.145, pp.449-459, 2019.

J. Boström, Alterations of the Tumor Suppressor Genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in Atypical and Anaplastic Meningiomas, Am. J. Pathol, vol.159, pp.661-669, 2001.

B. J. Pereira, S. M. Oba-shinjo, A. N. De-almeida, and S. K. Marie, Molecular alterations in meningiomas: Literature review, Clin. Neurol. Neurosurg, vol.176, pp.89-96, 2019.

V. E. Clark, Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas, Nat. Genet, vol.48, pp.1253-1259, 2016.

, Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment, Histol. Histopathol, vol.1, 2019.

S. Suppiah, Molecular and translational advances in meningiomas, Neuro-Oncol, vol.21, pp.4-17, 2019.

S. He, A review of epigenetic and gene expression alterations associated with intracranial meningiomas, Neurosurg. Focus, vol.35, p.5, 2013.

R. Kamps, Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification, Int. J. Mol. Sci, vol.18, 2017.

S. Yohe and B. Thyagarajan, Review of Clinical Next-Generation Sequencing, Arch. Pathol. Lab. Med, vol.141, pp.1544-1557, 2017.

C. Xu, M. R. Nezami-ranjbar, Z. Wu, J. Dicarlo, and Y. Wang, Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller, BMC Genomics, vol.18, p.5, 2017.

D. T. Proctor, S. Ramachandran, S. Lama, and G. R. Sutherland, Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms, World Neurosurg, vol.119, pp.366-373, 2018.

M. Al-rashed, K. Foshay, and M. Abedalthagafi, Recent Advances in Meningioma Immunogenetics. Front. Oncol, vol.9, p.1472, 2020.

D. E. Reuss, Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations, Acta Neuropathol. (Berl.), vol.125, pp.351-358, 2013.

M. Abedalthagafi, Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma, Neuro-Oncol, vol.18, pp.649-655, 2016.

B. Domingo-arrué, Molecular progression in unusual recurrent non-pediatric intracranial clear cell meningioma, Curr. Oncol, vol.24, p.244, 2017.

Ü. Yesilöz, Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence, Neuro-Oncol, vol.19, pp.1088-1096, 2017.

M. Youngblood, Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas, J. Neurosurg, vol.1, issue.10, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02549269

M. Karsy, Clinical potential of meningioma genomic insights: a practical review for neurosurgeons, Neurosurg. Focus, vol.44, p.10, 2018.

M. Preusser, P. K. Brastianos, and C. Mawrin, Advances in meningioma genetics: novel therapeutic opportunities, Nat. Rev. Neurol, vol.14, pp.106-115, 2018.

M. J. Smith, Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas, J. Pathol, vol.234, pp.436-440, 2014.

T. San-miguel, Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur, Hum. Pathol, vol.84, pp.105-114, 2019.

A. Olar, Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma, Acta Neuropathol. (Berl.), vol.133, pp.431-444, 2017.

F. Nassiri, DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management, Neuro-Oncol, vol.21, pp.901-910, 2019.

F. Sahm, DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis, Lancet Oncol, vol.18, pp.682-694, 2017.

D. Pietrasz, Quel avenir pour l'ADN tumoral circulant ? État des lieux et perspectives dans les cancers colorectaux, pulmonaires non à petites cellules et pancréatiques, Bull. Cancer (Paris), vol.103, pp.55-65, 2016.

F. Cheng, L. Su, and C. Qian, Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer, Oncotarget, vol.7, 2016.

G. Siravegna, S. Marsoni, S. Siena, and A. Bardelli, Integrating liquid biopsies into the management of cancer, Nat. Rev. Clin. Oncol, vol.14, pp.531-548, 2017.

S. Y. Shen, Sensitive tumour detection and classification using plasma cell-free DNA methylomes, Nature, vol.563, pp.579-583, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01974928

D. Mattos-arruda and L. , Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma, Nat. Commun, vol.6, 2015.

M. Peyre, De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors, Neuro oncol, vol.20, pp.1113-1121, 2018.